LivaNova (LIVN) – Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of LivaNova (NASDAQ: LIVN) recently:

• 5/7/2026 – LivaNova was upgraded by Weiss Ratings from “sell (d+)” to “hold (c)”.
• 5/7/2026 – LivaNova had its price target raised by Barclays PLC from $73.00 to $76.00. They now have an “equal weight” rating on the stock.
• 5/7/2026 – LivaNova had its price target raised by Mizuho from $85.00 to $90.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – LivaNova had its price target lowered by Robert W. Baird from $78.00 to $76.00. They now have an “outperform” rating on the stock.

Insider Activity

In related news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the sale, the director directly owned 7,228 shares in the company, valued at approximately $547,521. The trade was a 19.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.35% of the company’s stock.

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.